JMP Securities analyst Liisa Bayko said BioCryst shares should react favorably to FDA acceptance of the NDA for berotralstat as well as the FDA's indication of no Advisory Committee, or AdComm, meeting being planned. Her due diligence suggests there is a strong desire among physicians for an oral prophylactic option for HAE and a willingness to trade off some efficacy, which she thinks is not well appreciated by the market. Bayko, who assign berotralstat an 80% probability of success, reiterates her Outperform rating and $10 price target on BioCryst Pharmaceuticals shares.